

Transcriptomic study of probenecid on injured spinal cords in mice

Yu-Xin Zhang^{Equal first author, 1, 2, 3}, Sai-Nan Wang^{Equal first author, 1, 2}, Jing Chen^{1, 2}, Jian-Guo Hu^{Corresp., 1, 2}, He-Zuo Lü^{Corresp. 1, 2}

¹ Clinical Laboratory, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China

² Anhui Key Laboratory of Tissue Transplantation, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China

³ Department of Biochemistry and Molecular Biology, Bengbu Medical College, Bengbu, China

Corresponding Authors: Jian-Guo Hu, He-Zuo Lü

Email address: jghu9200@163.com, lhz233003@163.com

Background . Recent studies have found that probenecid has neuroprotective and repairing roles for central nervous system (CNS) injury. However, its effect on genome-wide transcription in acute spinal cord injury (SCI) remains unknown. Therefore, in the present study, RNA sequencing (RNA-Seq) was used to analyze the effect of probenecid on the local expression of gene transcription 8 h following injury. **Methods.** An Infinite Horizon impactor was used to perform contusive SCI in mice. The SCI model was made by using a rod (1.3 mm diameter) with a force of 50 Kdynes. Sham-operated (sham) mice only received a laminectomy without contusive injury. The spinal cord injured mice were randomly assigned into the control (SCI_C) or probenecid injection (SCI_P) group. The drug was intraperitoneal injected (0.5mg/kg, intraperitoneally) immediately following injury. Eight hours after operation, the spinal cords were removed. The total RNAs were extracted and purified for library preparation and transcriptomesequencing. Differential gene expressions (DEGs) of three groups were analyzed using the DESeq. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of DEGs were performed using Goseq R package and KOBAS. Real-time quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR) was used to validate RNA-Seq results. **Results.** RNA-Seq showed that, as compared with the SCI_C group, the number of DEGs was 641 in the SCI_P group (286 upregulated and 355 downregulated). According to GO analysis, DEGs were most enriched in extracellular matrix, collagen trimer, protein bounding and sequence specific DNA binding. KEGG analysis showed that the most enriched pathways included Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, ECM-receptor interaction, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Focal adhesion, Rap1 signaling pathway, etc. The sequence data have been deposited into Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra/PRJNA554464>).

1 **Transcriptomic study of probenecid on injured spinal**
2 **cords in mice**

3

4 Yu-Xin Zhang^{1,2,3&}, Sai-Nan Wang^{1,2&}, Jing Chen^{1,2}, Jian-Guo Hu^{1,2*}, He-Zuo Lü^{1,2*}

5

6 ¹ Clinical Laboratory, the First Affiliated Hospital of Bengbu Medical College, Anhui 233004,
7 P.R. China

8 ²Anhui Key Laboratory of Tissue Transplantation, the First Affiliated Hospital of Bengbu
9 Medical College, Anhui 233004, P.R. China

10 ³Department of Biochemistry and Molecular Biology, Bengbu Medical College, Anhui 233030,
11 P.R. China

12

13 & These authors contributed equally to this work

14

15 * Co-corresponding authors:

16 Jian-Guo Hu

17 Email address: jghu9200@163.com

18 He-Zuo Lü

19 Email address: lhz233003@163.com

20

21 Please address correspondence to:

22 He-Zuo Lü, M.D. Ph.D., Professor

23 Anhui Key Laboratory of Tissue Transplantation

24 the First Affiliated Hospital of Bengbu Medical College

25 287 Chang Huai Road

26 Bengbu 233004, P.R. China

27 Tel: +86-552-3170692

28 E-mail: lhz233003@163.com

29

30

31

32

33

34 Abstract

35

36 **Background.** Recent studies have found that probenecid has neuroprotective and repairing roles
37 for central nervous system (CNS) injury. However, its effect on genome-wide transcription in
38 acute spinal cord injury (SCI) remains unknown. Therefore, in the present study, RNA
39 sequencing (RNA-Seq) was used to analyze the effect of probenecid on the local expression of
40 gene transcription 8 h following injury.

41 **Methods.** An Infinite Horizon impactor was used to perform contusive SCI in mice. The SCI
42 model was made by using a rod (1.3 mm diameter) with a force of 50 Kdynes. Sham-operated
43 (sham) mice only received a laminectomy without contusive injury. The spinal cord injured mice
44 were randomly assigned into the control (SCI_C) or probenecid injection (SCI_P) group. The
45 drug was intraperitoneal injected (0.5mg/kg, intraperitoneally) immediately following injury.
46 Eight hours after operation, the spinal cords were removed. The total RNAs were extracted and
47 purified for library preparation and transcriptome sequencing. Differential gene expressions
48 (DEGs) of three groups were analyzed using the DESeq. Gene Ontology (GO) and Kyoto
49 Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of DEGs were performed
50 using Goseq R package and KOBAS. Real-time quantitative reverse-transcriptase polymerase
51 chain reaction (RT-qPCR) was used to validate RNA-Seq results.

52 **Results.** RNA-Seq showed that, as compared with the SCI_C group, the number of DEGs was
53 641 in the SCI_P group (286 upregulated and 355 downregulated). According to GO analysis,
54 DEGs were most enriched in extracellular matrix, collagen trimer, protein bounding and
55 sequence specific DNA binding. KEGG analysis showed that the most enriched pathways
56 included Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, ECM-receptor
57 interaction, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Focal adhesion, Rap1
58 signaling pathway, etc. The sequence data have been deposited into Sequence Read Archive
59 (<https://www.ncbi.nlm.nih.gov/sra/PRJNA554464>).

60

61 Introduction

62 Spinal cord injury (SCI) is defined as a variety of injuries to the spinal cord. According to the
63 severity of injury, the symptoms may vary, ranging from pain to complete loss of movement and
64 sensory function. SCI affects millions of people worldwide and usually affects patients for life
65 (Friedli et al. 2015). In the United States, the incidence of SCI ranges from 12,000 to 20,000
66 cases a year, with more than 280,000 patients sitting in wheelchairs (Singh et al. 2014). In the
67 past decade, the SCI cases in China have increased tenfold, and now 60,000 cases are increased
68 every year (Qiu 2009). SCI has a high rate of disability and mortality, which brings heavy burden
69 to patients, families and society (Krueger et al. 2013). Therefore, it is self-evident to explore the
70 effective treatment methods for repairing SCI in order to improve the quality of life of patients
71 and reduce the burden of social medical care.

72 According to the different stages, the pathological processes following traumatic SCI can be
73 divided into primary injury and secondary injury (Geisler et al. 2002; McDonald & Sadowsky
74 2002). Primary injury refers to the direct injury of the spinal cord by mechanical force, including
75 compression, contusion, laceration and penetration. Secondary injury refers to edema, ischemia,
76 local inflammation and electrolyte changes. These changes can cause accumulation of lipid
77 peroxides and oxygen free radicals, release of inflammatory factors and proteases, and lead to a
78 large number of cell apoptosis or necrosis, which further aggravates the damage of neurons and
79 axons (Ahuja et al. 2017; Oyinbo 2011; Tran et al. 2018).

80 Probenecid is an organic anion transport protein inhibitor, which has been widely used in clinic
81 (Hagos et al. 2017; Tollner et al. 2015). For example, probenecid has been used as a synergist in
82 the treatment of gout and antibiotics (Baranova et al. 2004; Papadopoulos & Verkman 2008). It
83 can reduce the degree of cognitive impairment in rats with cognitive impairment (Mawhinney et
84 al. 2011). It can also reverse cerebral ischemic injury and cellular inflammation (Wei et al. 2015;
85 Xiong et al. 2014). The combination of probenecid and N-Acetylcysteine could produce additive
86 effects by maintaining intracellular GSH concentrations and inhibiting neuronal death after
87 traumatic stretch injury (Du et al. 2016). Some studies had reported that probenecid can also
88 reduce neuropathic pain in the spinal cord (Bravo et al. 2014; Pineda-Farias et al. 2013).
89 Therefore, these reports indicate that probenecid has neuroprotective and repairing roles for
90 central nervous system (CNS) injury. However, whether the drug can play a role in SCI and
91 whether it can affect the gene expression profiles in injured spinal cords remain unknown.
92 Therefore, in the present study, probenecid was injected intraperitoneally into spinal cord injured
93 mice immediately after injury. Eight hours after operation, the spinal cords were removed, and
94 RNA-Seq was used to analyze the changes of transcriptome expression in the injured area, then
95 the key molecules and signal pathways were screened and identified, and provided new
96 theoretical and experimental basis for SCI clinical treatment.

97

98 **Materials & Methods**

99 **Animals**

100 A total of 27 healthy and clean C57BL/6 female mice (18-20g, 8 weeks old) were used to model
101 SCI. The animal care and use committee of Bengbu Medical College provided full approval for
102 this research (037/2017). Animal care following surgery was in compliance with the regulations
103 for the management of experimental animals (revised by the Ministry of Science and Technology
104 of China in June 2004), as well as the guidelines and policies on rodent survival surgery
105 provided by the Animal Care and Use Committee of Bengbu Medical College.

106 **Contusive SCI and drug injection**

107 An Infinite Horizon impactor (Precision Systems & Instrumentation, Lexington, KY) was used
108 to perform contusive SCI. The mice were firstly anesthetized with 50 mg/kg pentobarbitally, then
109 the T9 lamina was excised, the SCI model was created using a rod (1.3 mm diameter) with a
110 force of 50 Kdynes. Sham-operated (sham) mice only received a laminectomy without contusive
111 injury.

112 The spinal cord injured mice were randomly assigned to the solvent control (SCI_C) or
113 probenecid injection (SCI_P) group. The solvent or probenecid (0.5mg/kg) was intraperitoneally
114 injection immediately following injury. The solution (pH 7.3) was prepared as previously
115 described (Hainz et al. 2017).

116 **RNA isolation, quantification and qualification**

117 Eight hours after operation, the mice were anesthetized and perfused with 10 ml PBS, and then
118 the spinal cords (0.5 cm including the injury center) were removed. The total RNAs from spinal
119 cords were extracted and purified as previously described (Shi et al. 2017).

120 **Library preparation and transcriptome sequencing**

121 The sequencing libraries were produced by using NEBNext® Ultra™ RNA Library Prep Kit for
122 Illumina® (NEB, USA) as previously described (Shi et al. 2017). Finally, the 125 bp/150 bp
123 paired-end reads were obtained and sequenced on an Illumina Hiseq platform.

124 **Analysis of differentially expressed gene (DEG)**

125 Prior to DEG analysis,, the gene expression statistics were analyzed by using RSEM software
126 (<http://deweylab.biostat.wisc.edu/rsem/>) to convert the read count numbers to Fragments Per
127 Kilobase of transcript per Million fragments mapped (FPKM), and Principal Component
128 Analysis (PCA) analysis was made to determine the similarity and difference of data. DEGs of
129 three groups were analyzed as previously described (Shi et al. 2017) by using the DESeq
130 software (<http://www.bioconductor.org/>). Benjamini and Hochberg's approach was used to
131 control the false discovery rate and adjust the P-values. The adjusted P-value < 0.05 was defined
132 as a standard for significant differences in gene expression. In addition to FPKM hierarchical
133 clustering analysis of DEGs, we further analyzed the subclusters based on log₂ (ratios) of the
134 gene expression level relative to that of sham group. The log₂ (ratios) in SCI_C group ≥ 1 or ≤ -1
135 was used as a cut-off for subcluster analysis. The clustering algorithm divided the DEGs which
136 have similar expression trends into several subclusters.

137 **Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment** 138 **analysis of DEGs**

139 The GO and KEGG analysis were performed by using Goseq R package and KOBAS software
140 as previously described (Shi et al. 2017). In GO analysis, DEGs were implemented by the Goseq
141 R package, in which gene length bias was corrected. GO terms with corrected P value ≤ 0.05
142 were considered significantly enriched by DEGs. KEGG is a database resource for understanding
143 high-level functions and utilities of the biological system (<http://www.genome.jp/kegg/>). In this
144 study, we used KOBAS software to test the statistical enrichment of DEGs in KEGG pathways.

145 **Real-time quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)**

146 To validate RNA-Seq results, 9 DEGs were randomly selected and verified by RT-qPCR
147 according to our previous methods (Shi et al. 2017). The analysis was performed in 6 samples,
148 which included 3 independent samples and the 3 same samples used for the RNA-seq analysis.
149 PCR primer sequences are listed in Table 1. The relative quantitative results of each group of
150 genes were calculated according to the formula of $^{-\Delta\Delta Ct}$ (Livak & Schmittgen 2001). The
151 statistical values (n=6/group) were presented as mean ± standard deviation (SD). The data were
152 analyzed using one-way ANOVA followed by Student–Newman–Keuls tests. Statistical
153 differences were considered significant at P < 0.05.

154

155 **Results**

156 **Identification of expressed transcripts the mice spinal cords**

157 For the quality assessment of sequencing data, nine cDNA libraries were established, including
158 sham (sham_1, sham_2 and sham_3), SCI_C (SCI_C1, SCI_C2 and SCI_C3) and SCI_P
159 (SCI_P1, SCI_P2 and SCI_P3). RNA-Seq produced 48,848,744 - 61,037,096 raw reads for each
160 sample. After filtering out the low-quality reads, the clean reads were 48,226,002 - 60,037,772,
161 with the Q30 (%) 93.67 - 94.31 (Table 2).

162 In order to identify the source of variation in the original data, PCA analysis was conducted. As
163 shown in Fig.1, PC1, PC2 and PC3 were 54.51, 12.33 and 7.09%, respectively. The distance
164 between SCI_C (or SCI_P) and sham was obvious. Although the distance between SCI_P and
165 sham is not too far, it is sufficient for the analysis. These demonstrated that the data could be
166 used for the next analysis.

167 **Effect of SCI and probenecid treatment on gene expression**

168 RPKM and DESeq were used to analyze the gene expression level and differential expression
169 profiles, respectively. The results showed that, as compared with the sham group, there were
170 4,617 DEGs inthe SCI_C group, including 2,904 upregulated and 1,713 downregulated genes

171 (Fig.2A and Table S1). As compared with the SCI_C group, there were 641 different genes in
172 the SCI_P group, 286 were upregulated and 355 were downregulated (Fig.2B and Table S1). The
173 sequence data have been deposited into Sequence Read Archive
174 (<https://www.ncbi.nlm.nih.gov/sra/PRJNA554464>).

175 **RT-qPCR identification of DEGs**

176 In order to verify the RNA-Seq results, nine DEGs were randomly selected from the SCI_P
177 group, as compared with the SCI_C group, namely *Itga1*, *Lamb1*, *Cldn5*, *Lama2*, *CD34*, *Esam*,
178 *Setdb2*, *Agrn* and *Ccnt2*. The RNA-Seq and RT-qPCR results indicated that the expression
179 patterns of these DEGs were similar (Fig.3).

180 **Cluster Analysis of DEGs**

181 The DEGs from different groups were analyzed using FPKM hierarchical cluster analysis. As
182 shown in Fig. 4, DEGs were classified into different expression clusters by hierarchical
183 clustering. These clusters contained upregulated or downregulated DEGs. Most upregulated
184 DEGs in the SCI_C group as compared with the sham group, were in the middle and upper
185 clusters, while downregulated DEGs were observed in the lower cluster. As compared with the
186 sham group, most upregulated DEGs in the SCI_P group were in the upper cluster, while
187 downregulated DEGs were mainly observed in the lower cluster. As compared with the SCI_C
188 group, some upregulated DEGs in the SCI_P group were observed in upper cluster, while
189 downregulated DEGs were observed in the middle cluster; there were also some clusters with no
190 significant differences.

191 In addition to FPKM hierarchical clustering analysis of DEGs, the subclusters which have
192 similar expression trends were further analyzed. The \log_2 (ratios) in SCI_C group ≥ 1 or ≤ -1
193 was used as a cut-off for subcluster analysis. As shown in Fig. 5, we found several subclusters
194 with similar expression trends. Based on \log_2 (ratios) of the gene expression level relative to that
195 of sham group, the \log_2 (ratios) of all gene expression levels in sham group were zero. Fig. 5 A
196 and B showed that the two subclusters were strongly upregulated following SCI, and then
197 downregulated upon probenecid treatment. Fig. 5 C and D showed that the two subclusters were
198 strongly downregulated following SCI, and then upregulated upon probenecid treatment. In Fig.
199 5A, six genes (*Cybb*, *Esam*, *Itgam*, *Itgb2*, *Msn* and *Ncf2*) were involved in the leukocyte
200 transendothelial migration signaling pathway; six genes (*Col4a1*, *ErbB2*, *Flt4*, *Nos3*, *Syk* and
201 *Thbs4*) were involved in the PI3K-Akt signaling pathway. In Fig. 5B, three genes (*Cyba*, *Ncf1*
202 and *Rac2*) were involved in the NADPH oxidases; two genes (*Cflar* and *Tnfrsf10b*) were
203 involved in the TRAIL signaling pathway; eight genes (*Cd63*, *Cyba*, *Ddx58*, *Fcer1g*, *Lyn*, *Myh9*,
204 *Ncf1* and *Psmb8*) were involved in the innate immune system. In Fig. 5C and D, no gene can be
205 clustered into valuable signaling pathways.

206 **Go enrichment analysis of DEGs**

207 As compared with the sham group, there were seventy-eight GO terms in upregulated DEGs
208 (Fig.6A, Table S2) and nine GO terms in downregulated DEGs (Fig.6B, Table S2) in the SCI_C
209 group. The upregulated DEGs were most enriched in binding, protein binding, chemokine
210 activity, chemokine receptor binding, G-protein coupled receptor binding, anion binding, small
211 GTPase mediated signal transduction, immune system process, immune response, etc. The
212 downregulated DEGs were most enriched in protein binding, binding, extracellular-glutamate-
213 gated ion channel activity, acid phosphatase activity, transporter activity, mannose metabolic
214 process, excitatory extracellular ligand-gated ion channel activity, transmembrane transporter
215 activity, anion transmembrane and transporter activity. In SCI_P group, we observed three GO
216 terms in downregulated DEGs (Fig.6C, Table S3) and no valuable terms in upregulated DEGs

217 (Table S3) as compared with the SCI_C group. The downregulated DEGs were protein binding,
218 binding and sequence-specific DNA binding.

219 **KEGG enrichment analysis of DEGs**

220 Scatter plot were used to express the KEGG enrichment analysis results for the DEGs. As
221 compared with the sham group, the upregulated DEGs in the SCI_C group were most enriched in
222 TNF, NF-kappa B, cytokine-cytokine receptor interaction, Toll-like receptor, Leukocyte
223 transendothelial migration, PI3K-Akt, Focal adhesion, apoptosis, etc. (Fig.7A, Table S4); the
224 downregulated DEGs were most enriched in glutamatergic synapse, basal cell carcinoma, axon
225 guidance, other glycan degradation and nicotine addiction (Fig.7B, Table S4). In the SCI_P
226 group vs SCI_C group, only “ECM-receptor interaction” was enriched in the upregulated DEGs
227 (Fig.7C, Table S5); the downregulated DEGs were enriched in cell adhesion molecules (CAMs),
228 malaria, leukocyte transendothelial migration, ECM-receptor interaction, PI3K-Akt signaling
229 pathway, hematopoietic cell lineage, focal adhesion, Rap1 signaling pathway and amoebiasis
230 (Fig.7D, Table S5).

231

232 **Discussion**

233 Recent studies have shown that probenecid has neuroprotective and repairing effects in the
234 process of brain disorders (Wei et al. 2015; Xiong et al. 2014). However, its effect on genome-
235 wide transcription in acute spinal cord injury (SCI) is still unknown. Therefore, in this study,
236 RNA-Seq was used to analyze the effect of probenecid on the local expression of gene
237 transcription eight hours after SCI. The results showed that, as compared with the sham group,
238 there were 4,617 DEGs in the SCI_C group, including 2,904 upregulated and 1,713
239 downregulated genes. As compared with the SCI_C group, there were 641 DEGs in the SCI_P
240 group, 286 were upregulated and 355 were downregulated. These are consistent with others and
241 our previous reports (Chen et al. 2013; Shi et al. 2017). It also shows that the results of this
242 experiment are reliable. As compared with the SCI_C, there were 641 DEGs in the SCI_P group,
243 286 were upregulated and 355 were downregulated. To further verify the RNA-seq results, we
244 randomly selected 9 DEGs (Itga1, Lamb1, Cldn5, Lama2, CD34, Esam, Setdb2, Agrn and
245 Ccnt2) for RT-qPCR. The results showed that the expression patterns of these genes detected by
246 these two methods were similar, indicating that our RNA-seq results are reliable and can be used
247 for subsequent analysis. These also confirmed that probenecid can alter gene transcription after
248 SCI.

249 In order to further analyze the DEGs effected by probenecid, we used GO enrichment which can
250 reflect the distribution of DEGs on GO term enriched in cell components, molecular functions
251 and biological processes (Huang et al. 2013). In the SCI_P vs SCI_C group, the analysis showed
252 that there were 3 GO terms in downregulated DEGs (protein binding, binding and sequence-
253 specific DNA binding) and no valuable terms in upregulated DEGs. KEGG analysis showed that
254 the valuable signaling pathways associated with these DEGs included CAMs, leukocyte
255 transendothelial migration, ECM-receptor interaction, PI3K-Akt signaling pathway,
256 hematopoietic cell lineage, focal adhesion, Rap1 signaling pathway, etc.

257 Among these signal pathways, some have been reported to be related to SCI, such as CAMs
258 (Brook et al. 2000; Zhang et al. 2008), ECM-receptor interaction (Zhou et al. 2017), PI3K-Akt
259 signaling pathway (Li et al. 2019a; Li et al. 2019b; Zhang et al. 2017) and focal adhesion
260 (Chuang et al. 2018; Graham et al. 2016; Hao et al. 2018).

261 Following SCI, probenecid treatment could downregulate some genes, subclusters and signaling
262 pathways. Leukocyte transendothelial migration from the blood into tissues is vital for immune

263 surveillance and inflammation (Cook-Mills 2006). There is a large amount of leukocyte
264 infiltration in the pathological process of SCI. The infiltration of leukocytes need bind to
265 endothelial cell adhesion molecules and then migrate between vascular endothelial cells (Wang
266 et al. 2011). Therefore, the inhibition of leukocyte transendothelial migration and CAMs induced
267 by probenecid may play a role in inhibiting inflammation by weakening the infiltration of white
268 blood cells in the injured area. In this study, we clustered six genes (Cybb, Esam, Itgam, Itgb2,
269 Msn and Ncf2) involved in this pathway. Their expression is strongly downregulated following
270 SCI, and then upregulated upon probenecid treatment. This just proves that probenecid treatment
271 following SCI can play an anti-inflammatory role by inhibiting the infiltration of inflammatory
272 cells.

273 The ECM plays an important role in tissue and organ morphogenesis (Bonnans et al. 2014;
274 Rabelink et al. 2017) and control of cellular activities such as adhesion, migration,
275 differentiation, proliferation and apoptosis (Yue 2014). Focal adhesions are specialized
276 intracellular sites in which aggregated integrin receptors interact with extracellular matrices,
277 while extracellular matrices interact with intracellular actin cytoskeleton (BurrIDGE 2017;
278 LaFlamme et al. 2018). At the same time, focal adhesions are the result of cell-extracellular
279 matrix (ECM) interactions (BurrIDGE 2017; De Pascalis & Etienne-Manneville 2017). ECM and
280 Focal adhesions are downregulated after probenecid treatment, indicating that probenecid might
281 improve SCI by inhibiting adhesion, migration, differentiation, proliferation and apoptosis.
282 It has been reported that PI3K-Akt signaling fuses a variety of extracellular and intracellular
283 signal transduction pathways that regulate macrophage biology, including the production of pro-
284 inflammatory cytokines, phagocytosis, autophagy and homeostasis (Vergadi et al. 2017). PI3K-
285 Akt signal pathway is downregulated in SCI after probenecid treatment, and there are six genes
286 (Col4a1, Erbb2, Flt4, Nos3, Syk and Thbs4) being clustered into this pathway, indicating that
287 probenecid might improve SCI by regulating macrophages and inhibiting inflammatory
288 pathways. This is likely to provide important clues into the mechanism of action of probenecid.
289 The relationship between hematopoietic cell lineage pathway and SCI was found in a report on
290 the bioinformatics analysis of SCI (Zhu et al. 2017). Its specific role has not been reported yet,
291 and deserves further discussion.

292 Rap1 signal pathway plays an important role in regulating cell-cell and cell-matrix interactions
293 by regulating the function of adhesion molecules (Kim et al. 2011; Pollan et al. 2018). In our
294 study, Rap1 signaling pathway was enriched in downregulated DEGs of SCI after probenecid
295 treatment, suggesting that probenecid may inhibit cell adhesion and polarization by inhibiting the
296 Rap1 signaling pathway, thereby inhibiting inflammation.

297 In addition, three genes (Cyba, Ncf1 and Rac2) related to the NADPH oxidases, two genes (Cflar
298 and Tnfrsf10b) related to the TRAIL signaling pathway and eight genes (Cd63, Cyba, Ddx58,
299 Fcer1g, Lyn, Myh9, Ncf1 and Psmb8) related to the innate immune system were also strongly
300 downregulated following probenecid treatment. We know that NADPH oxidases is involved in
301 oxidative stress, TRAIL signaling pathway mediates inflammation and apoptosis, and the
302 immune system is involved in almost all pathological processes of injury (Chyuan et al. 2018;
303 Ewald 2018; Tisato et al. 2018). Therefore, probenecid treatment can play a neuroprotective role
304 by inhibiting immune response, oxidative stress, anti-inflammation and anti-apoptosis after SCI.

305 **Conclusions**

306 Acute SCI can lead to changes of mRNAs in injured spinal cords. These mRNAs and their
307 related pathways could provide some explanations for the pathological mechanism of acute SCI.
308 More interestingly, we also demonstrated that probenecid can lead to gene expression inhibitions

309 in the acute injured spinal cord. These downregulated DEGs and their associated signaling
310 pathways, such as focal adhesion, leukocyte transendothelial migration, ECM-receptor
311 interaction, PI3K-Akt, Rap1, are mainly related to inflammatory response, local hypoxia,
312 macrophage differentiation, adhesion migration and apoptosis of local cells. This suggests that
313 the application of probenecid in acute phase can improve the local microenvironment of SCI.
314 However, whether probenecid can be used as a therapeutic drug for SCI still needs to be further
315 explored. Next, the detailed research on this subject will be conducted by combining animal
316 models and clinical practice.

317

318 References

- 319 Ahuja CS, Nori S, Tetreault L, Wilson J, Kwon B, Harrop J, Choi D, and Fehlings MG. 2017.
320 Traumatic Spinal Cord Injury-Repair and Regeneration. *Neurosurgery* 80:S9-S22.
321 10.1093/neuros/nyw080
- 322 Baranova A, Ivanov D, Petrash N, Pestova A, Skoblov M, Kelmanson I, Shagin D, Nazarenko S,
323 Geraymovych E, Litvin O, Tiunova A, Born TL, Usman N, Staroverov D, Lukyanov S,
324 and Panchin Y. 2004. The mammalian pannexin family is homologous to the invertebrate
325 innexin gap junction proteins. *Genomics* 83:706-716. 10.1016/j.ygeno.2003.09.025
- 326 Bonnans C, Chou J, and Werb Z. 2014. Remodelling the extracellular matrix in development and
327 disease. *Nat Rev Mol Cell Biol* 15:786-801. 10.1038/nrm3904
- 328 Bravo D, Ibarra P, Retamal J, Pelissier T, Laurido C, Hernandez A, and Constandil L. 2014.
329 Pannexin 1: a novel participant in neuropathic pain signaling in the rat spinal cord. *Pain*
330 155:2108-2115. 10.1016/j.pain.2014.07.024
- 331 Brook GA, Houweling DA, Gieling RG, Hermanns T, Joosten EA, Bar DP, Gispen WH, Schmitt
332 AB, Leprince P, Noth J, and Nacimiento W. 2000. Attempted endogenous tissue repair
333 following experimental spinal cord injury in the rat: involvement of cell adhesion
334 molecules L1 and NCAM? *Eur J Neurosci* 12:3224-3238.
- 335 Burridge K. 2017. Focal adhesions: a personal perspective on a half century of progress. *FEBS J*
336 284:3355-3361. 10.1111/febs.14195
- 337 Chen K, Deng S, Lu H, Zheng Y, Yang G, Kim D, Cao Q, and Wu JQ. 2013. RNA-seq
338 characterization of spinal cord injury transcriptome in acute/subacute phases: a resource
339 for understanding the pathology at the systems level. *PLoS One* 8:e72567.
340 10.1371/journal.pone.0072567
- 341 Chuang YC, Lee CH, Sun WH, and Chen CC. 2018. Involvement of advillin in somatosensory
342 neuron subtype-specific axon regeneration and neuropathic pain. *Proc Natl Acad Sci U S*
343 *A* 115:E8557-E8566. 10.1073/pnas.1716470115
- 344 Chyuan IT, Tsai HF, Wu CS, Sung CC, and Hsu PN. 2018. TRAIL-Mediated Suppression of T
345 Cell Receptor Signaling Inhibits T Cell Activation and Inflammation in Experimental
346 Autoimmune Encephalomyelitis. *Front Immunol* 9:15. 10.3389/fimmu.2018.00015
- 347 Cook-Mills JM. 2006. Hydrogen peroxide activation of endothelial cell-associated MMPs during
348 VCAM-1-dependent leukocyte migration. *Cell Mol Biol (Noisy-le-grand)* 52:8-16.
- 349 De Pascalis C, and Etienne-Manneville S. 2017. Single and collective cell migration: the
350 mechanics of adhesions. *Mol Biol Cell* 28:1833-1846. 10.1091/mbc.E17-03-0134
- 351 Du L, Empey PE, Ji J, Chao H, Kochanek PM, Bayir H, and Clark RS. 2016. Probenecid and N-
352 Acetylcysteine Prevent Loss of Intracellular Glutathione and Inhibit Neuronal Death after
353 Mechanical Stretch Injury In Vitro. *J Neurotrauma* 33:1913-1917. 10.1089/neu.2015.4342

- 354 Ewald CY. 2018. Redox Signaling of NADPH Oxidases Regulates Oxidative Stress Responses,
355 Immunity and Aging. *Antioxidants (Basel)* 7. 10.3390/antiox7100130
- 356 Friedli L, Rosenzweig ES, Barraud Q, Schubert M, Dominici N, Awai L, Nielson JL, Musienko
357 P, Nout-Lomas Y, Zhong H, Zdunowski S, Roy RR, Strand SC, van den Brand R, Havton
358 LA, Beattie MS, Bresnahan JC, Bezar E, Bloch J, Edgerton VR, Ferguson AR, Curt A,
359 Tuszynski MH, and Courtine G. 2015. Pronounced species divergence in corticospinal tract
360 reorganization and functional recovery after lateralized spinal cord injury favors primates.
361 *Sci Transl Med* 7:302ra134. 10.1126/scitranslmed.aac5811
- 362 Geisler FH, Coleman WP, Benzel E, Ducker T, and Hurlbert RJ. 2002. Spinal cord injury. *Lancet*
363 360:1883; author reply 1884. 10.1016/s0140-6736(02)11744-2
- 364 Graham ZA, Qin W, Harlow LC, Ross NH, Bauman WA, Gallagher PM, and Cardozo CP. 2016.
365 Focal adhesion kinase signaling is decreased 56 days following spinal cord injury in rat
366 gastrocnemius. *Spinal Cord* 54:502-509. 10.1038/sc.2015.183
- 367 Hagos FT, Daood MJ, Ocque JA, Nolin TD, Bayir H, Poloyac SM, Kochanek PM, Clark RS, and
368 Empey PE. 2017. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases
369 plasma and brain exposure of N-acetylcysteine. *Xenobiotica* 47:346-353.
370 10.1080/00498254.2016.1187777
- 371 Hainz N, Wolf S, Beck A, Wagenpfeil S, Tschernig T, and Meier C. 2017. Probenecid arrests the
372 progression of pronounced clinical symptoms in a mouse model of multiple sclerosis. *Sci*
373 *Rep* 7:17214. 10.1038/s41598-017-17517-5
- 374 Hao M, Ji XR, Chen H, Zhang W, Zhang LC, Zhang LH, Tang PF, and Lu N. 2018. Cell cycle and
375 complement inhibitors may be specific for treatment of spinal cord injury in aged and
376 young mice: Transcriptomic analyses. *Neural Regen Res* 13:518-527. 10.4103/1673-
377 5374.226405
- 378 Huang Q, Wu LY, Wang Y, and Zhang XS. 2013. GOMA: functional enrichment analysis tool
379 based on GO modules. *Chin J Cancer* 32:195-204. 10.5732/cjc.012.10151
- 380 Kim C, Ye F, and Ginsberg MH. 2011. Regulation of integrin activation. *Annu Rev Cell Dev Biol*
381 27:321-345. 10.1146/annurev-cellbio-100109-104104
- 382 Krueger H, Noonan VK, Trenaman LM, Joshi P, and Rivers CS. 2013. The economic burden of
383 traumatic spinal cord injury in Canada. *Chronic Dis Inj Can* 33:113-122.
- 384 LaFlamme SE, Mathew-Steiner S, Singh N, Colello-Borges D, and Nieves B. 2018. Integrin and
385 microtubule crosstalk in the regulation of cellular processes. *Cell Mol Life Sci* 75:4177-
386 4185. 10.1007/s00018-018-2913-x
- 387 Li H, Zhang X, Qi X, Zhu X, and Cheng L. 2019a. Icariin Inhibits Endoplasmic Reticulum Stress-
388 induced Neuronal Apoptosis after Spinal Cord Injury through Modulating the PI3K/AKT
389 Signaling Pathway. *Int J Biol Sci* 15:277-286. 10.7150/ijbs.30348
- 390 Li Y, Guo Y, Fan Y, Tian H, Li K, and Mei X. 2019b. Melatonin Enhances Autophagy and
391 Reduces Apoptosis to Promote Locomotor Recovery in Spinal Cord Injury via the
392 PI3K/AKT/mTOR Signaling Pathway. *Neurochem Res* 44:2007-2019. 10.1007/s11064-
393 019-02838-w
- 394 Livak KJ, and Schmittgen TD. 2001. Analysis of relative gene expression data using real-time
395 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25:402-408.
396 10.1006/meth.2001.1262
- 397 Mawhinney LJ, de Rivero Vaccari JP, Dale GA, Keane RW, and Bramlett HM. 2011. Heightened
398 inflammasome activation is linked to age-related cognitive impairment in Fischer 344 rats.
399 *BMC Neurosci* 12:123. 10.1186/1471-2202-12-123

- 400 McDonald JW, and Sadowsky C. 2002. Spinal-cord injury. *Lancet* 359:417-425. 10.1016/S0140-
401 6736(02)07603-1
- 402 Oyinbo CA. 2011. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this
403 multiply cascade. *Acta Neurobiol Exp (Wars)* 71:281-299.
- 404 Papadopoulos MC, and Verkman AS. 2008. Potential utility of aquaporin modulators for therapy
405 of brain disorders. *Prog Brain Res* 170:589-601. 10.1016/S0079-6123(08)00446-9
- 406 Pineda-Farias JB, Perez-Severiano F, Gonzalez-Esquivel DF, Barragan-Iglesias P, Bravo-
407 Hernandez M, Cervantes-Duran C, Aguilera P, Rios C, and Granados-Soto V. 2013. The
408 L-kynurenine-probenecid combination reduces neuropathic pain in rats. *Eur J Pain*
409 17:1365-1373. 10.1002/j.1532-2149.2013.00305.x
- 410 Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You
411 S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, and
412 Knudsen BS. 2018. Regulation of inside-out beta1-integrin activation by CDCP1.
413 *Oncogene* 37:2817-2836. 10.1038/s41388-018-0142-2
- 414 Qiu J. 2009. China Spinal Cord Injury Network: changes from within. *Lancet Neurol* 8:606-607.
415 10.1016/S1474-4422(09)70162-0
- 416 Rabelink TJ, van den Berg BM, Garsen M, Wang G, Elkin M, and van der Vlag J. 2017.
417 Heparanase: roles in cell survival, extracellular matrix remodelling and the development
418 of kidney disease. *Nat Rev Nephrol* 13:201-212. 10.1038/nrneph.2017.6
- 419 Shi LL, Zhang N, Xie XM, Chen YJ, Wang R, Shen L, Zhou JS, Hu JG, and Lu HZ. 2017.
420 Transcriptome profile of rat genes in injured spinal cord at different stages by RNA-
421 sequencing. *BMC Genomics* 18:173. 10.1186/s12864-017-3532-x
- 422 Singh A, Tetreault L, Kalsi-Ryan S, Nouri A, and Fehlings MG. 2014. Global prevalence and
423 incidence of traumatic spinal cord injury. *Clin Epidemiol* 6:309-331.
424 10.2147/CLEP.S68889
- 425 Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, Secchiero P, Bergamini C, Trentini
426 A, Bonaccorsi G, Valacchi G, Zuliani G, and Cervellati C. 2018. TRAIL and
427 Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation
428 and Oxidative Stress. *Mediators Inflamm* 2018:9629537. 10.1155/2018/9629537
- 429 Tollner K, Brandt C, Romermann K, and Loscher W. 2015. The organic anion transport inhibitor
430 probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide. *Eur J*
431 *Pharmacol* 746:167-173. 10.1016/j.ejphar.2014.11.019
- 432 Tran AP, Warren PM, and Silver J. 2018. The Biology of Regeneration Failure and Success After
433 Spinal Cord Injury. *Physiol Rev* 98:881-917. 10.1152/physrev.00017.2017
- 434 Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, and Tsatsanis C. 2017. Akt Signaling Pathway
435 in Macrophage Activation and M1/M2 Polarization. *J Immunol* 198:1006-1014.
436 10.4049/jimmunol.1601515
- 437 Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, and Mackman N. 2011.
438 Monocytic microparticles activate endothelial cells in an IL-1beta-dependent manner.
439 *Blood* 118:2366-2374. 10.1182/blood-2011-01-330878
- 440 Wei R, Wang J, Xu Y, Yin B, He F, Du Y, Peng G, and Luo B. 2015. Probenecid protects against
441 cerebral ischemia/reperfusion injury by inhibiting lysosomal and inflammatory damage in
442 rats. *Neuroscience* 301:168-177. 10.1016/j.neuroscience.2015.05.070
- 443 Xiong XX, Gu LJ, Shen J, Kang XH, Zheng YY, Yue SB, and Zhu SM. 2014. Probenecid protects
444 against transient focal cerebral ischemic injury by inhibiting HMGB1 release and

- 445 attenuating AQP4 expression in mice. *Neurochem Res* 39:216-224. 10.1007/s11064-013-
446 1212-z
- 447 Yue B. 2014. Biology of the extracellular matrix: an overview. *J Glaucoma* 23:S20-23.
448 10.1097/IJG.000000000000108
- 449 Zhang F, Ru N, Shang ZH, Chen JF, Yan C, Li Y, and Liang J. 2017. Daidzein ameliorates spinal
450 cord ischemia/reperfusion injury-induced neurological function deficits in Sprague-
451 Dawley rats through PI3K/Akt signaling pathway. *Exp Ther Med* 14:4878-4886.
452 10.3892/etm.2017.5166
- 453 Zhang Y, Yeh J, Richardson PM, and Bo X. 2008. Cell adhesion molecules of the immunoglobulin
454 superfamily in axonal regeneration and neural repair. *Restor Neurol Neurosci* 26:81-96.
- 455 Zhou J, Xiong Q, Chen H, Yang C, and Fan Y. 2017. Identification of the Spinal Expression Profile
456 of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by
457 Sequence Analysis. *Front Mol Neurosci* 10:91. 10.3389/fnmol.2017.00091
- 458 Zhu Z, Wang D, Jiao W, Chen G, Cao Y, Zhang Q, and Wang J. 2017. Bioinformatics analyses of
459 pathways and gene predictions in IL-1alpha and IL-1beta knockout mice with spinal cord
460 injury. *Acta Histochem* 119:663-670. 10.1016/j.acthis.2017.07.007

461

462 **Figures**

463

464 **Figure 1 PCA analysis**

465

466 PCA analysis was performed using three principal components (PC1, 2, and 3) to demonstrate the
467 source of variance (n=3).

468

469 **Figure 2 Volcano map of DEGs**

470

471 Red, green and blue dots represent significantly upregulated, downregulated and no changed gene
472 expressions, respectively. (A) SCI_C vs Sham; (B) SCI_P vs SCI_C.

473

474 **Figure 3 RT-qPCR verification of DEGs characterized by RNA-Seq**

475

476 A: The longitudinal coordinates in RNA-Seq were the mRNA expression level (read counts, n =
477 3). B: The longitudinal coordinates in RT-qPCR were the mRNA expression level calculated using
478 the $\Delta\Delta C_t$ method and expressed relative to the value in the sham group (designated as 1). All data
479 were calculated with mean \pm standard deviation (n = 6, which included 3 independent samples and
480 the 3 same samples used for the RNA-seq analysis). **P < 0.01 (ANOVA).

481

482 **Figure 4 Hierarchical cluster analysis of DEGs**

483

484 The DEGs in different groups were analyzed using FPKM hierarchical cluster analysis. The read
485 count numbers of FPKM were converted by RSEM software. DEGs were classified into different
486 expression cluster by hierarchical clustering. The colour scheme (red to blue) represents the up to
487 down of the gene expression. sham: sham group; SCI_C: SCI (solvent control) group; SCI_P: SCI
488 (probenecid) group.

489

490 **Figure 5 Subcluster analysis of DEGs**

491 The subclusters of DEGs which have similar expression trends were further analyzed. The log₂
492 (ratios) in SCI_C group ≥ 1 or ≤ -1 was used as a cut-off. Based on log₂ (ratios) of the gene
493 expression level relative to that of sham group, the log₂ (ratios) of all gene expression levels in
494 sham group were zero. A and B: the two subclusters which were strongly upregulated following
495 SCI, and then downregulated upon probenecid treatment. C and D: the two subclusters which
496 were strongly downregulated following SCI, and then upregulated upon probenecid treatment.

497

498 **Figure 6 GO enrichment analysis of DEGs**

499

500 DEGs were implemented by the Goseq R package, in which gene length bias was corrected. GO
501 terms with corrected P value ≤ 0.05 were considered significantly enriched by DEGs. The asterisk
502 (*) represent significant enrichment terms ($P \leq 0.05$). A: GO analysis of upregulated DEGs in
503 SCI_C vs sham group; B: GO analysis of downregulated DEGs in SCI_C vs sham group; C: GO
504 analysis of downregulated DEGs in SCI_P vs SCI_C group.

505

506 **Figure 7 KEGG enrichment analyses of DEGs**

507

508 KOBAS software was used to test the statistical enrichment of DEGs in KEGG pathways. In this
509 figure, KEGG enrichment is measured by Rich factor, Qvalue and the number of genes enriched
510 in the related pathway. Rich factor refers to the ratio of the number of differentiated genes
511 (sample number) enriched in the pathway to the number of annotated genes (background
512 number). The larger the Rich factor, the greater the degree of enrichment. Qvalue is the Pvalue
513 after multiple hypothesis test correction. The range of Qvalue is between 0 and 1. The closer the
514 Qvalue is to 0, the more significant the enrichment is. The KEGG pathways were shown in A:
515 upregulated DEGs (SCI_C vs sham); B: downregulated DEGs; C: upregulated DEGs (SCI_P vs
516 SCP_C); D: downregulated DEGs (SCI_C vs sham).

517

518 **Tables**

519

520 Table 1 PCR primers used in the study

521 Table 2 Summary of sequence assembly after Illumina sequencing

522

523 **Supplementary materials**

524 Table S1 DEGs of different groups

525 Table S2 GO enrichment analysis of SCI_C vs sham group

526 Table S3 GO enrichment analysis of SCI_P vs SCI_C group

527 Table S4 KEGG analysis of SCI_C vs sham group

528 Table S5 KEGG analysis of SCI_P vs SCI_C group

529

530

Figure 1

Figure 1 PCA analysis

PCA analysis was performed using three principal components (PC1, 2, and 3) to demonstrate the source of variance (n=3).




Figure 2

Figure 2 Volcano map of DEGs

Red, green and blue dots represent significantly upregulated, downregulated and no changed gene expressions, respectively. (A) SCI_C vs Sham; (B) SCI_P vs SCI_C.




Figure 3

Figure 3 RT-qPCR verification of DEGs characterized by RNA-Seq

A: The longitudinal coordinates in RNA-Seq were the mRNA expression level (read counts, $n = 3$). B: The longitudinal coordinates in RT-qPCR were the mRNA expression level calculated using the $\Delta\Delta\text{Ct}$ method and expressed relative to the value in the sham group (designated as 1). All data were calculated with mean \pm standard deviation ($n = 6$, which included 3 independent samples and the 3 same samples used for the RNA-seq analysis). $**P < 0.01$ (ANOVA).





Figure 4

Figure 4 Hierarchical cluster analysis of DEGs

The DEGs in different groups were analyzed using FPKM hierarchical cluster analysis. The read count numbers of FPKM were converted by RSEM software. DEGs were classified into different expression cluster by hierarchical clustering. The colour scheme (red to blue) represents the up to down of the gene expression. sham: sham group; SCI_C: SCI (solvent control) group; SCI_P: SCI (probenecid) group.




Figure 5

Figure 5 Subcluster analysis of DEGs

The subclusters of DEGs which have similar expression trends were further analyzed. The \log_2 (ratios) in SCI_C group ≥ 1 or ≤ -1 was used as a cut-off. Based on \log_2 (ratios) of the gene expression level relative to that of sham group, the \log_2 (ratios) of all gene expression levels in sham group were zero. A and B: the two subclusters which were strongly upregulated following SCI, and then downregulated upon probenecid treatment. C and D: the two subclusters which were strongly downregulated following SCI, and then upregulated upon probenecid treatment.

A

Name	sham	SCI	CSCI	P
Rgs16	0	1.78	1.07	
Col4a1	0	1.7	0.9	
Apobec3	0	1.66	1.29	
Syk	0	1.65	0.89	
Akr1b8	0	1.64	1.18	
Ifi35	0	1.62	1.21	
Thbs4	0	1.61	1.2	
Esam	0	1.61	0.49	
Pstpip2	0	1.59	0.58	
Sdc1	0	1.58	1.05	
Gda	0	1.58	0.85	
A2m	0	1.57	1.42	
Dok2	0	1.57	0.66	
Nupr1	0	1.57	0.85	
Aoc3	0	1.57	-0.41	
Zfp429	0	1.54	0.65	
Lox4	0	1.53	1.05	
Capg	0	1.52	0.9	
Tnfrsf11b	0	1.52	1.37	
Timeless	0	1.51	1.09	
Plek	0	1.51	0.96	
Naip2	0	1.51	1.22	
Arhgef5	0	1.49	0.59	
Slc1a5	0	1.48	0.68	
Plekha2	0	1.48	0.83	
Anxa2	0	1.47	1.05	
Cyp11b1	0	1.47	0.85	
Tbx3	0	1.46	0.29	
Tmem154	0	1.45	1	
Emp3	0	1.44	1.12	
Ptprc	0	1.43	0.57	
Ets1	0	1.42	0.68	
Mgp	0	1.41	0.28	
Il33	0	1.41	0.85	
Acat3	0	1.41	0.98	
Anxa3	0	1.4	0.97	
Cd52	0	1.4	0.22	
Ltrr	0	1.4	1.06	
Gjc1	0	1.4	0.87	
Igf1bp7	0	1.39	0.47	
Stom	0	1.39	0.91	
Gpr182	0	1.39	0.46	
Hmg2	0	1.39	0.81	
Steap3	0	1.39	0.73	
Nef2	0	1.37	0.96	
Plp2	0	1.37	0.77	
Phf11d	0	1.37	1.09	
Nos3	0	1.35	0.06	
Hspa4l	0	1.35	0.79	
Adam12	0	1.34	0.82	
Tgfb1	0	1.34	0.57	
Rdh12	0	1.33	0.66	
Marveld2	0	1.33	0.91	
Alox5ap	0	1.3	0.03	
Ap1s3	0	1.29	1.03	
Ampd1	0	1.29	-1.8	
Irgb2	0	1.29	0.33	
Ip6k3	0	1.28	1.04	
Snx20	0	1.28	0.5	
Flt4	0	1.27	0.31	
Spil	0	1.26	0.71	
Fblim1	0	1.24	0.81	
Filip1l	0	1.24	0.41	
Was	0	1.22	0.99	
Arhgap30	0	1.22	0.83	
Slc39a1	0	1.21	0.96	
Rin3	0	1.21	0.39	
Emilin1	0	1.21	0.7	
Erg	0	1.21	0.13	
Entpd1	0	1.2	0.46	
Notch4	0	1.2	0.43	
Pear1	0	1.19	0.08	
Hcls1	0	1.18	0.76	
Nfam1	0	1.17	0.49	
Parp10	0	1.16	0.81	
Dkk2	0	1.15	-0.12	
Zfp217	0	1.15	0.79	
Iqgap1	0	1.14	0.64	
Ier1	0	1.14	0.71	
Msn	0	1.13	0.73	
Icam2	0	1.13	0.1	
Ilgam	0	1.13	0.57	
Plekha4	0	1.12	-0.33	
Irf8	0	1.12	0.25	
C1ra	0	1.12	0.47	
Atp10a	0	1.11	0.51	
Slc25a24	0	1.1	0.74	
Cd33	0	1.1	0.68	
Tarm1	0	1.1	0.24	
Kcnj8	0	1.1	0.38	
Hmgcs2	0	1.09	-0.61	
Trim56	0	1.07	0.73	
Sp100	0	1.07	-0.1	
Tpm6	0	1.07	0.39	
Erb2	0	1.06	0.45	
Id3	0	1.06	0.51	
Tbxa2r	0	1.05	-0.96	
Foxq1	0	1.05	-0.44	
Myo1c	0	1.05	0.6	
Arhgdib	0	1.05	0.34	
Fbln2	0	1.04	0.3	
Apob	0	1.04	0.37	
Hk3	0	1.04	0.5	
Fxyd3	0	1.02	-0.32	
Cybb	0	1	-0.71	
Prrh1	0	1	0.33	

B

Name	sham	SCI	CSCI	P
Sox7	0	1.49	0.65	
S100a6	0	1.48	1.34	
Tnfrsf10b	0	1.48	0.96	
Lyn	0	1.42	1.2	
Trib3	0	1.4	1.03	
Tpm4	0	1.39	1.02	
Rac2	0	1.36	1.06	
Tec	0	1.3	1.15	
Wwtr1	0	1.29	1.03	
Slc5a3	0	1.27	1.09	
Yap1	0	1.27	0.98	
Feer1g	0	1.26	1.06	
Ecm1	0	1.25	0.61	
Ptpn12	0	1.25	1.08	
Itprip1	0	1.23	0.86	
Gpd1	0	1.22	1.1	
Id1	0	1.2	0.62	
S100a10	0	1.19	1	
Met	0	1.18	1.01	
Wisp1	0	1.18	1.01	
Slc2a1	0	1.18	0.72	
Twist1	0	1.17	0.26	
Mb21d1	0	1.17	0.88	
Ddx58	0	1.16	1.02	
Layn	0	1.16	1.12	
Tmem37	0	1.16	0.51	
Cavin1	0	1.15	0.65	
Ldha	0	1.14	0.74	
Lrrn4cl	0	1.14	0.28	
Cyba	0	1.14	0.56	
Adipor2	0	1.13	0.97	
Myh9	0	1.12	0.79	
Casp12	0	1.12	0.99	
Vsig2	0	1.11	0.4	
Fhl3	0	1.11	0.9	
Rhoc	0	1.11	0.91	
Rbpms	0	1.1	0.29	
Lrrc8a	0	1.1	0.98	
Xbp1	0	1.1	0.64	
Susd6	0	1.09	0.98	
Cdc42se1	0	1.07	1	
Myo1g	0	1.07	0.69	
Rph3al	0	1.07	0.72	
Nfya	0	1.06	-0.11	
Cflar	0	1.05	0.67	
Psm8	0	1.04	0.7	
Vgf	0	1.04	0.69	
Dll4	0	1.03	0.42	
Tnfaip8l1	0	1.03	0.84	
Ncf1	0	1.03	0.77	
Gypc	0	1.02	0.74	
Cd63	0	1.02	0.86	
Psd4	0	1.01	0.72	
Tspo	0	1	0.56	

C

Name	sham	SCI	CSCI	P
Snrnp40	0	-2.24	-1.44	
Ranbp3l	0	-2.18	-1.9	
Wdr49	0	-2.11	-0.93	
Ly6gef	0	-1.86	-1.72	
Lrrc43	0	-1.68	-1.49	
Gpr17	0	-1.52	-1.18	
Gli1	0	-1.44	-1.24	
Mob3b	0	-1.32	-1.24	
Hoxd1	0	-1.31	-0.87	
Rgs22	0	-1.28	-0.84	
Gdf7	0	-1.27	-0.99	
Cep72	0	-1.2	-0.75	
Vwa3a	0	-1.2	-0.86	
Dynlrb2	0	-1.2	-0.98	
Serpinb1	0	-1.19	-1	
Opn4	0	-1.17	-0.78	
Cd180	0	-1.17	-0.85	
Crb1	0	-1.12	-0.37	
Mxl1	0	-1.12	-0.98	
Fgfr2	0	-1.11	-0.87	
Dlec1	0	-1.1	-0.61	
Lrrc23	0	-1.08	-0.78	
Myh6	0	-1.06	-0.78	
Pls1	0	-1.05	-0.73	
Neil2	0	-1.05	-0.29	
Calr4	0	-1.04	-0.79	
Efs	0	-1.03	-0.87	
Adamts6	0	-1.03	-0.67	
Hhip	0	-1.02	-0.84	

D

Name	sham	SCI	CSCI	P
Gm6408	0	-1.63	-1.3	
Slc26a9	0	-3.9	0.009	
Olf1393	0	-3.4	-0.68	
Lrrc27	0	-3.04	-1.97	
Sis	0	-2.82	-1.26	
Vmn14	0	-2.65	0.032	
Ctcf	0	-2.54	0.263	
Klf14	0	-2.47	-0.77	
Esco2	0	-2.45	-1.34	
Olf1545	0	-2.38	0.12	
Gm47283	0	-2.31	-0.26	
Gm40460	0	-2.31	-0.71	
Wdr86	0	-2.28	-0.83	
Esrp1	0	-2.21	-0.51	
E2f8	0	-2.2	-1.93	
Oard1	0	-2.04	-2.05	
Emilin3	0	-2	1.398	
Tulp1	0	-1.91	-0.52	
Ccdc153	0	-1.9	-1.44	
Lmtd1	0	-1.89	-1.28	
Iqca	0	-1.89	-1	
Pitx1	0	-1.88	-1.59	
Tmem212	0	-1.87	-1.08	
Mc5r	0	-1.85	-1.28	
Smim5	0	-1.84	-1.27	
D6Erd527e	0	-1.84	0.325	
Ccdc146	0	-1.81	-0.66	
Colea6	0	-1.81	-0.06	
Nme9	0	-1.74	-1.43	
Fam166b	0	-1.72	-1.38	
Ildr1	0	-1.71	-0.99	
Adgrf4	0	-1.67	-0.18	
Lgr6	0	-1.66	-1.49	
BC024139	0	-1.65	-1.22	
Clqmf3	0	-1.62	-1.38	
Acp4	0	-1.61	0.21	
Dnah8	0	-1.6	-0.66	
Accs1	0	-1.6	1.376	
Stpg1	0	-1.59	-1.08	
Dnah11	0	-1.57	-0.7	
Ninj2	0	-1.57	-1.23	
Slc27a5	0	-1.55	-0.08	
Tex35	0	-1.54	0.708	
Rad9a	0	-1.53	1.005	
Fscn2	0	-1.52	1.093	
Ttc16	0	-1.52	-1.01	
Mom5	0	-1.47	-0.28	
Fmpd2	0	-1.47	-0.64	
Col24a1	0	-1.46	-0.24	
Lrit3	0	-1.43	0.398	
Atp10b	0	-1.43	-1.11	
Sctr	0	-1.4	-0.55	
Cfap70	0	-1.38	-0.41	
Vwa3b	0	-1.38	-0.59	
Cdhr3	0	-1.37	-0.64	
Siglech	0	-1.35	-1	
Angptl1	0	-1.34	-1.49	
Kctd14	0	-1.33	-0.79	
Abcg5	0	-1.33	1.534	
Ing4	0	-1.31	-0.23	
Gm10775	0	-1.29	-0.07	
Mpp4	0	-1.29	0.129	
Mcm10	0	-1.27	0.212	
Neu4	0	-1.26	-1.14	
Aip1	0	-1.25	1.265	
Olfml1	0	-1.24	-1.02	
Cubn	0	-1.24	-0.12	
Barx2	0	-1.23	-0.31	
Slc34a3	0	-1.19	-0.83	
Tmem210	0	-1.17	-0	
Adamts19	0	-1.16	-0.43	
Cavin4	0	-1.16	-0.7	
Coll1a1	0	-1.13	-0.26	
H2-BI	0	-1.13	-0.45	
Nudh8	0	-1.12	-0.32	
Chrd	0	-1.12	-0.41	
Cfap44	0	-1.12	-0.1	
Cascl	0	-1.1	-0.24	
Gipr	0	-1.1	-0.65	
Ccdc162	0	-1.09	-0.56	
Tnfrsf4	0	-1.09	-0.41	
Pesk4	0	-1.08	-0.41	
Fxyd2	0	-1.05	-0.57	
Kif20b	0	-1.05	-0.58	
Pld6	0	-1.04	-0.44	
Entpd4b	0	-1.03	-0	
Coll1a2	0	-1.03	-0.47	
Riad1	0	-1.02	-0.43	
Ager	0	-1.01	-0.17	
Catsperd	0	-1.01	-0.26	
Rxfp1	0	-1.01	-0.48	
Smc1b	0	-1	0.496	
F2r13	0	-1	-0.2	
Poln	0	-1	-0.24	

DOWN


UP

Figure 6


Figure 6 GO enrichment analysis of DEGs

DEGs were implemented by the GOrseq R package, in which gene length bias was corrected. GO terms with corrected P value ≤ 0.05 were considered significantly enriched by DEGs. The asterisk (*) represent significant enrichment terms ($P \leq 0.05$). A: GO analysis of upregulated DEGs in SCI_C vs sham group; B: GO analysis of downregulated DEGs in SCI_C vs sham group; C: GO analysis of downregulated DEGs in SCI_P vs SCI_C group.


A Enriched GO Terms (SCI_C vs sham) **UP**



B Enriched GO Terms (SCI_C vs sham) **DOWN**



C The Most Enriched GO Terms (SCI_P vs SCI_C) **DOWN**



type ■ biological_process ■ cellular_component ■ molecular_function

Figure 7

Figure 7 KEGG enrichment analyses of DEGs

KOBAS software was used to test the statistical enrichment of DEGs in KEGG pathways. In this figure, KEGG enrichment is measured by Rich factor, Qvalue and the number of genes enriched in the related pathway. Rich factor refers to the ratio of the number of differentiated genes (sample number) enriched in the pathway to the number of annotated genes (background number). The larger the Rich factor, the greater the degree of enrichment. Qvalue is the Pvalue after multiple hypothesis test correction. The range of Qvalue is between 0 and 1. The closer the Qvalue is to 0, the more significant the enrichment is. The KEGG pathways were shown in A: upregulated DEGs (SCI_C vs sham); B: downregulated DEGs; C: upregulated DEGs (SCI_P vs SCP_C); D: downregulated DEGs (SCI_C vs sham).




Table 1 (on next page)

Table 1 PCR primers used in the study

1 **Table 1 Real-time PCR primers used in the study**

2

Gene	Forward primer 5' - 3'	Reverse primer 5' - 3'
Itga1	TCAGTGGAGAGCAGATCGGA	CCTCGTCTGATTCACAGCGT
lamb1	TGCCTTTTCTCCCCGCTACC	CCATGTCCAGTCCTCGCAGA
Cldn5	TTCTATGATCCGACGGTGCC	CTTGACCGGGAAGCTGAACT
CD34	ACCACAGACTTCCCCAACTG	CATATGGCTCGGTGGGTGAT
lama2	GCATTAGTGAGCCGCCCTAT	TCTTTCAGGTCTCGTGTGGC
Esam	AGACTCTGGGACTTACCGCT	GGTCACATTGGTCCCGACAT
Setdb2	CCACAAATGGAGATCATAACCT	GCAGTGGGGCTTCCTTTTTC
Agri	CTCTGCCACTGGAACACAGA	GGAAAAGCAGCACCGCAAAG
Ccnt2	AGCAAGGATTTGGCACAGAC	CTCTAGGGTAACCGTGGGGT
beta-actin	AGAAGCTGTGCTATGTTGCTCTA	ACCCAAGAAGGAAGGCTGGAAAA

Table 2 (on next page)

Table 2 Summary of sequence assembly after Illumina sequencing

Sham: Sham_1, Sham_2, Sham_3; SCI (solvent control): SCI_C1, SCI_C2, SCI_C3; SCI

(probenecid): SCI_P1, SCI_P2, SCI_P3; Q20: The percentage of bases with a Phred value > 20;

Q30: The percentage of bases with a Phred value > 30.

1 **Table 2 Summary of sequence assembly after Illumina sequencing**

2

Sample name	Raw reads	Clean reads	clean bases	Error rate (%)	Q20 (%)	Q30 (%)	GC content (%)
Sham_1	56509230	55796658	8.37G	0.03	97.73	93.95	51.23
Sham_2	48848744	48226002	7.23G	0.03	97.6	93.67	51.71
Sham_3	58228350	57459748	8.62G	0.03	97.67	93.78	51.42
SCI_C1	58862872	58126844	8.72G	0.03	97.88	94.31	51.39
SCI_C2	56980070	56166058	8.42G	0.03	97.74	94.03	51.42
SCI_C3	59804518	58798224	8.82G	0.03	97.63	93.74	51.02
SCI_P1	54853344	53996254	8.1G	0.03	97.72	93.91	50.93
SCI_P2	56322736	55540308	8.33G	0.03	97.87	94.27	50.94
SCI_P3	61037096	60037772	9.01G	0.03	97.71	93.89	50.92

3 Sham: Sham_1, Sham_2, Sham_3; SCI (solvent control): SCI_C1, SCI_C2, SCI_C3; SCI (probenecid): SCI_P1, SCI_P2,

4 SCI_P3;

5 Q20: The percentage of bases with a Phred value > 20;

6 Q30: The percentage of bases with a Phred value > 30.

7